Drug-drug Interaction Study between Feminizing Hormone Therapy & Antiretroviral Therapy among trans women living with HIV


This is a clinical study to look at possible drug-drug interactions (DDIs) between antiretroviral therapy (ART - medication used to treat HIV) and feminizing hormone therapy (FHT - medications some trans women take as part of their transition). Because there is limited data about such drug-drug interactions between these two groups of drugs, this study is viral to address barriers to uptake to HIV treatment regimens (antiretroviral therapies) among trans women living with HIV.

In a previous pilot study, we measured trans women’s estradiol concentrations over an 8h period to identify the best time points to use to investigate potential drug-drug interactions.

We are also piloting our FHT satisfaction questionnaire (FEM-SQ) that assesses differences in FHT satisfaction among trans women with HIV taking ART and those without HIV not taking ART, as well changes in satisfaction related to new HIV treatment regimes over time.

We are recruiting participants for this study! 


We will be comparing estradiol concentrations between two groups of participants:

GROUP 1: TRANS WOMEN LIVING WITH & WITHOUT HIV

  • 18 years of age or older.

    •  Trans women living with HIV must be taking Biktarvy ® (medication to treat HIV), or willing to switch for the duration of study.

    • Trans women living without HIV and are not taking PrEP or PEP (medication to prevent HIV).

  • Currently taking 2mg or more of oral estradiol.

  • Currently taking an anti-androgen (or have a medical reason to not need it).

GROUP 2: CIS WOMEN LIVING WITH HIV

  • 18 years of age or older.

  • Not taking hormonal birth control.

  • Have a regular period.

  • Taking Biktarvy ® (medication to treat HIV), or willing to switch for the duration of study.

Click here for more information and to sign up for this study!